Last reviewed · How we verify
Monodral (penthienate)
Monodral (generic name: penthienate) is a penthienate drug. It is currently in unknown development for Gastric spasm, Peptic ulcer.
Monodral works by inhibiting the action of acetylcholine at muscarinic receptors in the gastrointestinal tract.
Monodral is a small molecule with anticholinergic properties, similar to atropine. It is used to treat conditions such as peptic ulcer and dyspepsia by reducing gastric motility and secretion.
At a glance
| Generic name | penthienate |
|---|---|
| Drug class | penthienate |
| Therapeutic area | Gastroenterology |
| Phase | unknown |
Mechanism of action
Think of it like a volume control for your stomach muscles. When you eat, your stomach muscles contract to mix food with digestive juices. Monodral helps slow down these muscle contractions, giving your stomach a break and reducing symptoms like cramps and nausea.
Approved indications
- Gastric spasm
- Peptic ulcer
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Monodral CI brief — competitive landscape report
- Monodral updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Monodral
What is Monodral?
How does Monodral work?
What is Monodral used for?
What is the generic name of Monodral?
What drug class is Monodral in?
What development phase is Monodral in?
Related
- Drug class: All penthienate drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Gastric spasm
- Indication: Drugs for Peptic ulcer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing